Digestive System TRIZ Cases

Novel FGFR inhibitor scaffolds use targeted substituent changes to retain inhibition and selectivity against wild-type and gatekeeper-mutant FGFRs.

Targeting IL-23 with guselkumab dosing helps control Crohn's inflammation, improve remission endpoints, and reduce adverse events.

Targeting IL-23p19 with staged IV induction and SC maintenance dosing helps induce and maintain remission in moderate to severe Crohn's disease.

RNASET2 with TL1A and IFN-γ helps separate severe IBD subgroups and identify patients more likely to benefit from anti-TL1A therapy.

Monoclonal antibodies tuned for TNFR2 improve target specificity while enabling agonist or antagonist control of Treg activity in cancer and autoimmune disease.

New Resmetirom polymorphs, co-crystals, and salts improve stability, processing, and dissolution for NASH and NAFLD formulations.

Thermoresponsive poloxamer gel enables single-session fistula treatment by forming an in situ barrier that supports faster, more durable mucosal healing.

Lyophilized buffalo milk whey in gastro-resistant capsules helps consolidate tight junctions and reduce intestinal permeability without drug-like side effects.

Targeting SH3YL1 with monoclonal antibodies helps suppress inflammatory pathways and limit tissue damage across kidney, liver, and bowel disease models.

A bispecific A33-DOTA binding format improves tumor uptake and therapeutic index in pretargeted radioimmunotherapy while limiting normal-tissue toxicity.

Combining a GUCY2C agonist with a short-chain fatty acid improves colorectal and intestinal treatment while reducing diarrhea and dehydration.

A targeted anti-IL-23p19 dosing regimen improves ulcerative colitis remission while limiting adverse reactions seen with broader IBD therapies.

Targeting CLDN18.2 extracellular loop 1, these antibody formats inhibit tumor growth, induce apoptosis, and can engage immune cells.

By targeting the heparan sulfate site on RAGE, these antibodies block oligomerization and signaling without broad pathway interference.

Fully human anti-TMPRSS6 antibodies block hemojuvelin cleavage to raise hepcidin and lower serum iron in iron overload disorders.

Weight-based resmetirom dosing improves NASH fibrosis treatment consistency and adjusts exposure when CYP2C8 inhibitors are used.

Safer sodium borohydride reduction and crystallization produce high-purity Type-A and Type-B m receptor antagonist crystals without toxic reagents.

Independent dual tangential flow modules scale bupivacaine MVL production while improving stability and reducing lipid degradation.

A pressureless-sintered zirconia composition balances natural tooth translucency and color tone with at least 500 MPa strength for front dentures.

A new Resmetirom crystal form uses safer solvent mediation and controlled crystallisation to improve solubility, stability, compressibility, and moisture resistance.

A mesenchymal stem cell, extracellular vesicle, and growth factor composition promotes liver repair while avoiding transplant risk.

7-position bile acid modification blocks bacterial conversion of UDCA into lithocholic acid while improving liver disease treatment efficacy.

Combining spirulina hydrolysate with Ascophyllum nodosum extract improves livestock digestibility, immune function, and methane reduction.

Combined RNAi agents target multiple HBV genome regions to suppress viral gene expression, reduce resistance risk, and support lasting remission.

A dissolving oral thin film uses permeation enhancers and gas generation to bypass swallowing difficulty and speed API absorption.

Immune-modulating fibroblasts help counter cachexia by suppressing inflammation and muscle wasting to restore metabolic homeostasis.

Autonomous GI release localizes PDE4 inhibitors to inflamed intestinal tissue, improving stability while limiting systemic exposure.

A Rubus longisepalus extract composition inhibits diffuse-type gastric cancer cell growth while aiming to reduce side effects on normal cells.

Neutralizing anti-HBsAg antibodies reduce circulating HBsAg and target HBV clearance beyond lifelong antiviral suppression.

TNFSF15 haplotype screening identifies likely anti-TL1A non-responders, helping guide IBD treatment toward higher remission rates.

A macrocyclic liver-specific and extracellular contrast combination improves CT and MRI liver imaging while reducing repeat injections and gadolinium retention.

A small-molecule PUMA inhibitor protects LGR5+ GI stem cells from chemotherapy-induced apoptosis without reducing antitumor activity.

Oral probiotics modulate intestinal microbiota to improve atopic dermatitis and reduce corticosteroid use without steroid-related adverse effects.

Adenosine receptor antagonists such as caffeine reduce ATP analog side effects and help maintain dose intensity in cancer treatment.

GA-functionalized liposomes bind CD71 on rare pDCs to improve selective vaccine and agent delivery without relying on non-specific targeting.

Targeting CLDN18.2-positive tumors with IMAB362 balances antitumor activity and low toxicity through selective ADCC, CDC, and apoptosis.

Selective THR-beta activation with resmetirom reduces liver volume in NASH and cirrhosis, improving perfusion and easing surgical access.

Novel anti-IL-15 antibody variants block IL-15 signaling to limit TRm cell activity and slow progression in IL-15-mediated diseases.

Targeting overexpressed HCN ion channels in TNBC helps reduce tumor size and suppress cancer stem cell proliferation with fewer side effects.

Repurposed PDE5 inhibitors reduce fibrotic markers and collagen deposition, slowing renal and pulmonary fibrosis progression.

Anti-MAA IgG levels provide a non-invasive way to distinguish ulcerative colitis from Crohn's disease with reliable diagnostic precision.

A tricyclic compound combined with HBsAg and reverse transcriptase inhibitors suppresses HBV replication, lowers HBsAg, and helps limit resistance.

A blood-based viral antibody signature improves early HCC detection in at-risk patients when ultrasound and AFP miss pre-symptomatic disease.

A 14-day rifabutin, amoxicillin, and omeprazole regimen maintains H. pylori eradication across BMI groups, reducing bariatric surgery delays.

A pan-PPAR agonist approach reduces liver fibrosis and inflammation while avoiding the severe side effects seen with corticosteroids.

Antihistamines lower PP-IX in protoporphyria, easing liver injury and skin photosensitivity without invasive surgery.

Defined antibody CDR sequences improve TL1A binding specificity while avoiding lengthy iterative construction for inflammation-related therapies.

Biodegradable microparticle implants deliver drugs directly to the intervertebral disc for sustained pain relief with less invasive treatment.

A multivalent oral vaccine combines ETEC antigens, LCTBA, and dmLT to extend protection to Salmonella and Shigella diarrheal disease.

Controlled deamidation, oxidation, and aggregation keep mepolizumab biologically active for treating IL-5 mediated diseases.

A nested chamber dosage form releases prebiotics before probiotics to improve mucosal receptivity and bacterial persistence in GI and urogenital delivery.

Selective pectin depolymerization tunes galectin-targeting activity to reduce inflammation and fibrosis without cytotoxicity.